Brain infarction
Conditions
Interventions
Aspirin group: aspirin 200mg/day Three months
Cilostazol group: cilostazol 200mg/day Three months
Sponsors
Kumamoto Acute Stroke Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Non-cardioembolic brain infarction (2) First or recurrent stroke (3) Within 48 hours after the onset (4) Patients who develop symptoms within 48 hours before starting the administration of the investigational drugs (5) Stable general condition
Exclusion criteria
Exclusion criteria: (1) Cardioembolic brain infarction (2) Contraindications to aspirin or cilostazol 1) Patients with hemorrhagic disease 2) Patients with Congestive heart failure 3) Patients known hypersensitivity to aspirin or cilostazol 4) Patients with pregnancy or potential pregnancy 5) Patients with active peptic ulcer 6) Patients with aspirin-induced asthma 7) Low birth weight infant, newborn and infant (3) Patients who should be treated with rt-PA (4) Patient who is taking aspirin or cilostazol at the time of admission (5) Patients who are considered unsuitable for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of the progressing stroke (worsening of the NIHSS score by 2 point or more) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Proportion of the patients with mRS score 0,1 or 2 at 3 months follow-up 2)Incidence of cardiovascular events 3)Incidence of hemorrhagic adverse events 4) Incidence of adverse events (without hemorrhagic stroke) | — |
Countries
Japan
Contacts
Public ContactTeruyuki Hirano
Kumamoto University Department of Neurology
Outcome results
None listed